CRDMOs offer a continuum of services from early discovery to clinical manufacturing, addressing solubility and stability challenges in NCE development. Advanced technologies like spray drying and ...
Proteolysis-targeting chimeras (PROTACs), particularly those incorporating the von Hippel–Lindau (VHL) E3 ligase ligand, present significant physicochemical challenges due to their large molecular ...
Formulation can make or break a development-stage protein drug, and add years of IP protection and value for post-patent molecules. Yet significant disagreement exists on the best time to undertake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback